Carrington and Swanson Health Sign Supply and Licensing Agreements for Manapol(R) Powder

IRVING, Texas, Sept 11, 2006 /PRNewswire-FirstCall via COMTEX/ -- Carrington Laboratories, Inc. (CARN) announced today it has entered into a two-year, non- exclusive supply agreement for Manapol(R) powder and a licensing agreement for the Manapol(R) trademark and logo with Swanson Health Products(TM) (SHP).

Under the terms of the agreements, Carrington will supply SHP with Manapol(R) powder for use in new product additions to its current Swanson(R) brand. In return, SHP will be responsible for the marketing and distributing of these products containing Manapol(R) powder to consumers via SHP's mail- order catalog business and web site. Swanson markets its products to over 1 million health-conscious people throughout the world.

"This is a great opportunity to further expand the Manapol(R) brand, penetrate new markets and increase the awareness of Manapol(R)'s nutraceutical benefits to an important, health-conscious audience," stated Ms. Pamela Schonbeck, Carrington's Senior Director, Sales and Marketing, Consumer Services.

Manapol(R) is a high-quality ingredient and fits within SHP's corporate policy of providing the highest quality dietary supplements. Carrington's facilities in Costa Rica and Texas are ISO certified and produce products under current good manufacturing practices (cGMP) as recognized by the FDA and, thus meet or exceed SHP's quality control requirements.
Carrington's proprietary "product by process" production provides the only consistent, batch-to-batch raw materials from Aloe vera L. Therefore, SHP customers can be assured that each lot of Manapol(R) powder will contain consistent and known levels of the polymeric acetylated mannans, recognized as the active chemical backbone in gel from Aloe vera L.

About Manapol(R) Powder
Manapol(R) powder is a patented, "product by process" from the inner gel of the Aloe vera L. plant, with an average molecular weight greater than one million daltons. It is regulated as a dietary supplement ingredient and carries a DSHEA claim for immune-enhancing support. Manapol(R) can be used in a variety of dietary supplements, such as capsules, tablets, liquids, powder blends, and power bars, and works synergistically with a variety of vitamins and botanicals. The unique composition of matter for Manapol(R) consists of polymeric acetylated mannans, fiber, unique pectins, and calcium malate, which provides nutritional benefit for the immune system, bone health and digestion.

About Swanson Health Products
Swanson Health Products, an independently owned and operated company based in Fargo, North Dakota, was founded by Leland Swanson in 1969 as a mail-order business dedicated to providing quality nutritional supplements at affordable prices with a strong emphasis on customer service. The company has grown to become one of America's largest privately held, mail-order and internet marketers of dietary supplements with global sales and distribution channels.

In the competitive supplement industry, Swanson's commitment to quality, affordability and customer service sets it apart. GMP-certified facilities and stringent Quality Control systems ensure supplements from Swanson contain only the finest and freshest ingredients. All Swanson products are backed by a 100% money-back satisfaction guarantee. More information regarding Swanson's continuing mission of Bringing Wellness to the World, one person at a time, can be found at or by calling 1-800-437-4148.

About Carrington
Carrington Laboratories, Inc., is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards.

Carrington's wholly-owned subsidiary, DelSite Biotechnologies, Inc. is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen. This work is partially funded by two grants from the Department of Health and Human Services.

Carrington and DelSite technologies are protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit .
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed August 14, 2006.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.